Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Up 37.3% in November

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the recipient of a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 3,350,000 shares, a growth of 37.3% from the November 15th total of 2,440,000 shares. Based on an average daily trading volume, of 680,400 shares, the short-interest ratio is presently 4.9 days. Approximately 3.8% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CNTA. Guggenheim lifted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a research note on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. BMO Capital Markets lifted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Finally, Jefferies Financial Group increased their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Price Performance

NASDAQ CNTA traded down $0.30 on Friday, hitting $16.57. The stock had a trading volume of 873,593 shares, compared to its average volume of 429,306. The firm has a 50-day moving average of $16.50 and a 200-day moving average of $13.30. The company has a market capitalization of $2.18 billion, a price-to-earnings ratio of -10.83 and a beta of 1.52. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals has a 52-week low of $6.65 and a 52-week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Equities analysts expect that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 2,592 shares of Centessa Pharmaceuticals stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $15.32, for a total value of $39,709.44. Following the sale, the chief executive officer now owns 630,661 shares of the company’s stock, valued at approximately $9,661,726.52. The trade was a 0.41 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gregory M. Weinhoff sold 16,619 shares of the firm’s stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $15.69, for a total transaction of $260,752.11. Following the sale, the insider now owns 206,750 shares of the company’s stock, valued at approximately $3,243,907.50. The trade was a 7.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 262,624 shares of company stock worth $4,497,698 in the last 90 days. Insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC lifted its stake in Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares during the last quarter. Quarry LP boosted its position in Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after buying an additional 3,108 shares during the period. Sandia Investment Management LP bought a new position in shares of Centessa Pharmaceuticals during the second quarter valued at about $90,000. Finally, Fred Alger Management LLC purchased a new position in shares of Centessa Pharmaceuticals in the second quarter worth about $99,000. 82.01% of the stock is currently owned by institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.